Sheep lameness is the most significant welfare problem in UK sheep farming and a major issue globally. Survey data consistently shows 3–10% of UK sheep are lame at any given time, with higher rates in wet conditions and housed flocks. Across a flock's annual cycle, 15–20% of sheep may experience a lameness episode. In commercial flocks of 500+ ewes, this translates to tens to hundreds of lame animals at any given time.
Beyond the UK, lameness is a major welfare concern in sheep farming in Australia, New Zealand, Europe, and wherever sheep are intensively managed. The financial costs — reduced weight gain, reduced milk production, poor reproductive performance, and treatment costs — are estimated at £80–150 per lame sheep per episode in UK production systems. Despite this economic burden, treatment is often delayed, averaging 4–7 days after owners first notice lameness.
Sheep have historically been considered stoic animals that mask pain — a perception that has contributed to under-treatment of lameness. Research has fundamentally revised this understanding. Sheep with footrot (the most common cause of lameness) show:
The Sheep Pain Facial Action Unit System (SPFAS), developed at Newcastle University and validated in studies published 2021–2024, enables objective pain scoring in sheep by assessing ear position, orbital tightening, cheek tension, lip commissure tension, and nasal plane shape. This system is increasingly used in research and being adapted for farm-level assessment tools.
Importantly, pain persists even after treatment — antibiotic treatment for footrot reduces infection but may not resolve pain immediately. Studies show meloxicam (an NSAID) administered at treatment significantly improves welfare outcomes compared to antibiotic treatment alone, both by reducing pain and improving treatment success rates.
CODD is caused by Treponema bacteria and produces severe, rapidly progressive hoof lesions — often described as the worst-welfare lameness condition in sheep. CODD begins with a break in skin at the coronary band and can destroy the hoof capsule within days. It spreads rapidly through flocks and is highly painful. Treatment requires oxytetracycline injection and topical antibiotic application. Prevention requires footbathing and biosecurity to prevent introduction of Treponema from cattle (where the same bacteria cause digital dermatitis).
Footrot (caused by Dichelobacter nodosus) is the most common cause of sheep lameness globally. It causes separation of the hoof horn from the sensitive laminae, producing severe pain and distinctive foul-smelling interdigital lesions. Management combines antibiotic treatment (individual injection), topical treatment, footbathing (zinc sulfate), and vaccination with footrot vaccines available in the UK, New Zealand, and Australia. New strains of D. nodosus with antibiotic resistance have emerged, making vaccination increasingly important.
White line disease (separation of the white line with accumulation of debris) is common and causes moderate lameness. Foot abscesses (solear or periarticular abscesses) cause severe pain and may require drainage. Improved hoof trimming technique and surface management reduce incidence. Overtrimming itself can cause lameness — a common iatrogenic welfare problem.
FMD (vesicular disease affecting all cloven-hoofed animals) produces extremely painful mouth and foot lesions. While FMD-free status is maintained in the UK and most EU countries, Australia, and North America, FMD remains endemic in large parts of Africa, Asia, and the Middle East, where it causes significant lameness-related welfare problems in sheep populations.
Research consistently documents that farmers delay treating lame sheep. A 2023 survey found that the median time from farmers first noticing a lame sheep to initiating treatment was 5 days. Key barriers include: difficulty in catching individual sheep from large outdoor flocks; the time cost of bringing sheep in for treatment; uncertainty about diagnosis and appropriate treatment; and historically, an underestimation of sheep pain by farmers.
Intervention programs addressing these barriers have succeeded in reducing treatment delays. The AHDB (Agriculture and Horticulture Development Board) "Five Point Plan" for lameness control, widely promoted in the UK, sets a target of treating lame sheep within 3 days of noticing lameness. Farms following the Five Point Plan have achieved significant reductions in lameness prevalence — some achieving below 2% prevalence from baselines of 10%+.
In 2025, the AHDB Five Point Plan has been integrated into Red Tractor and Quality Assurance scheme requirements for UK sheep farms, creating an incentive for adoption beyond voluntary uptake.
Pain management in sheep lameness remains under-utilized despite clear evidence of benefit. Meloxicam (Metacam) is licensed for cattle and pigs in the EU/UK but used off-label for sheep. Research shows that meloxicam treatment at the time of footrot antibiotic treatment improves welfare and treatment success rates. A 2024 RSPCA-commissioned study found only 35% of UK sheep farmers routinely use NSAIDs for lame sheep treatment.
Barriers to NSAID use include licensing gaps, cost, and administration practicality. Advocacy by the British Veterinary Association and RSPCA for improved sheep NSAID licensing is ongoing. Long-acting meloxicam formulations that cover the full antibiotic treatment course with a single injection would significantly improve uptake.
Genetic selection for footrot resistance is possible — heritability of susceptibility is approximately 0.15–0.35, allowing meaningful genetic progress. Some breeds (particularly Merino) are more susceptible. UK sheep breeding programs are exploring inclusion of lameness-relevant traits in breeding indices. New Zealand Merino breeding programs have achieved significant genetic progress in fleece footrot resistance through selective breeding. In 2025, genomic selection tools for lameness resistance are in development and expected to accelerate genetic progress.
Key priorities for sheep lameness welfare improvement in 2025 and beyond include: wider adoption of Five Point Plan standards through assurance schemes; improved NSAID licensing and uptake; development of point-of-care diagnostic tools to differentiate lameness causes (enabling appropriate treatment choice); precision livestock technology for automated early lameness detection (gait analysis systems for sheep are in pilot trials); and breeding program integration of welfare-relevant traits.
Tags: Sheep Lameness Pain Treatment Welfare 2025